mitoxantrone has been researched along with Acute Promyelocytic Leukemia in 72 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL)." | 9.11 | High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. ( Benner, A; del Valle y Fuentes, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Germing, U; Glasmacher, A; Götze, K; Grimminger, W; Hartmann, F; Hensel, M; Nerl, C; Petzer, A; Pralle, H; Salwender, H; Schlenk, RF; Zick, L, 2005) |
| "The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy." | 8.82 | Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. ( Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR, 2003) |
| "Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin." | 7.76 | Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. ( Byl, JA; Chang, C; Corser, R; Felix, CA; Grimwade, D; Hasan, SK; Hoyle, C; Lo-Coco, F; Mays, AN; Osheroff, N; Parker, AN; Peniket, A; Saravanamuttu, K; Solomon, E; Wiemels, JL; Xiao, Y, 2010) |
| "Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing-remitting or progressive multiple sclerosis (MS)." | 7.74 | Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. ( Baer, MR; Barcos, M; Chadha, MK; Heyman, MR; Ramkumar, B; Sait, SN, 2008) |
| "Mitoxantrone, the first immunosuppressant to receive FDA approval for treatment of worsening relapsing-remitting, secondary progressive, and progressive-relapsing multiple sclerosis (MS) is a DNA topoisomerase II inhibitor that has been associated with the development of acute promyelocytic myelogenous leukemia (APML)." | 7.74 | Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. ( Galetta, SL; Ko, MW; McGrath, C; Porter, D; Tamhankar, MA; Volpe, NJ, 2008) |
| "Therapeutic advances in acute promyelocytic leukemia (APL) have transformed it into today's most curable form of leukemia." | 5.91 | Assessing the Efficacy of Mitoxantrone and Doxorubicin as Frontline Anthracyclines During Induction Therapy of Newly Diagnosed Acute Promyelocytic Leukemia. ( Gómez-Almaguer, D; González-Treviño, M; Jaime-Pérez, JC; Meléndez-Flores, JD; Ramos-Dávila, EM, 2023) |
| "The aim of our study was to evaluate the impact of oral arsenic (the realgar-indigo naturalis formula, RIF) and all-trans retinoic acid (ATRA) on coagulopathy in acute promyelocytic leukemia (APL) compared with intravenous arsenic trioxide (ATO) and ATRA during induction." | 5.27 | The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. ( Guo, ZP; Huang, XJ; Jia, JS; Jiang, H; Jiang, Q; Zhu, HH, 2018) |
| "The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL)." | 5.11 | High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. ( Benner, A; del Valle y Fuentes, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Germing, U; Glasmacher, A; Götze, K; Grimminger, W; Hartmann, F; Hensel, M; Nerl, C; Petzer, A; Pralle, H; Salwender, H; Schlenk, RF; Zick, L, 2005) |
| "The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy." | 4.82 | Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. ( Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR, 2003) |
| "In this study, we compared the efficacy of mitoxantrone in combination with intermediate-dose cytarabine (HAM) with that of high-dose cytarabine alone (HiDAC) as consolidation regimens in non-acute promyelocytic leukemia (APL) acute myeloid leukemia patients with favorable and intermediate cytogenetics." | 3.88 | Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics. ( Hu, LN; Li, GQ; Lin, HQ; Shen, Q; Sun, XF; Zhang, XY; Zhou, JH, 2018) |
| "Reports of patients with secondary acute promyelocytic leukemia (APL) have increased in recent years, particularly for those who received treatment with mitoxantrone, and retrospective studies have suggested that their characteristics and outcomes were similar to those of patients with de novo APL." | 3.81 | Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. ( Adès, L; Beaumont, M; Bordessoule, D; Braun, T; Cereja, S; Chevret, S; Chomienne, C; Degos, L; Detourmignies, L; Dombret, H; Fenaux, P; Guerci, A; Lamy, T; Pigneux, A; Poiré, X; Raffoux, E; Recher, C; Spertini, O; Thomas, X; Tournilhac, O, 2015) |
| " We analyzed polymorphic variants of DNA repair and detoxification genes in patients with multiple sclerosis (MS) who developed secondary acute promyelocytic leukemia (sAPL), in most cases after treatment with mitoxantrone (MTZ)." | 3.77 | Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes. ( Bernardi, G; Buttari, F; Centonze, D; Cicconi, L; Garagnani, P; Hasan, SK; Hohaus, S; Lo-Coco, F; Mantovani, V; Marasco, E; Ottone, T; Sanz, MA; Voso, MT, 2011) |
| "Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin." | 3.76 | Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. ( Byl, JA; Chang, C; Corser, R; Felix, CA; Grimwade, D; Hasan, SK; Hoyle, C; Lo-Coco, F; Mays, AN; Osheroff, N; Parker, AN; Peniket, A; Saravanamuttu, K; Solomon, E; Wiemels, JL; Xiao, Y, 2010) |
| "Therapy-related acute leukaemia (TRAL) is a concern for neurologists and patients when considering treatment with Mitoxantrone for multiple sclerosis (MS)." | 3.75 | Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? ( Boggild, M; Ellis, R, 2009) |
| "Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing-remitting or progressive multiple sclerosis (MS)." | 3.74 | Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. ( Baer, MR; Barcos, M; Chadha, MK; Heyman, MR; Ramkumar, B; Sait, SN, 2008) |
| " However, cases are emerging after mitoxantrone therapy for multiple sclerosis (MS)." | 3.74 | Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. ( Amadori, S; Borlenghi, E; Byl, JA; Cattaneo, C; Cervera, J; Esteve, J; Felix, CA; Grimwade, D; Hasan, SK; La Nasa, G; Ledda, A; Lennard, A; Libura, M; Lo-Coco, F; Mays, AN; Melillo, L; Montefusco, E; Osheroff, N; Ottone, T; Sanz, MA; Satchi, G; Sperr, WR; Stephen, C; Voso, MT, 2008) |
| "Mitoxantrone, the first immunosuppressant to receive FDA approval for treatment of worsening relapsing-remitting, secondary progressive, and progressive-relapsing multiple sclerosis (MS) is a DNA topoisomerase II inhibitor that has been associated with the development of acute promyelocytic myelogenous leukemia (APML)." | 3.74 | Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. ( Galetta, SL; Ko, MW; McGrath, C; Porter, D; Tamhankar, MA; Volpe, NJ, 2008) |
| "We report two new cases of mitoxantrone-related leukemia occurring in two patients with multiple sclerosis (MS), 14 and 18 months after the last infusion of the drug." | 3.74 | Mitoxantrone-related acute leukemia in two MS patients. ( Gille, M; Goffette, S; Pielen, A; Sindic, CJ; Van Pesch, V, 2008) |
| "Drug-induced cleavage of DNA by topoisomerase II mediates the formation of chromosomal translocation breakpoints in mitoxantrone-related APL and in APL that occurs after therapy with other topoisomerase II poisons." | 3.73 | DNA topoisomerase II in therapy-related acute promyelocytic leukemia. ( Adès, L; Blair, IA; Cassinat, B; Chomienne, C; Cross, NC; Felix, CA; Fenaux, P; Grimwade, D; Lafage-Pochitaloff, M; Mason, A; Mistry, AR; Osheroff, N; Parry, A; Peniket, AJ; Reiter, A; Segal, MR; Solomon, E; Walz, C; Whitmarsh, RJ; Wiemels, JL, 2005) |
| "Mitoxantrone (MX) is an immunosupressant drug used in secondarily progressive multiple sclerosis (SPMS) and in relapsing-remitting multiple sclerosis (RRMS)." | 3.73 | Acute myeloid leukaemia induced by mitoxantrone: case report. ( Arruda, WO; de Oliveira, Mde S; Montú, MB; Ramina, R, 2005) |
| " Remission induction therapy was performed for a 46-year-old Japanese man with acute promyelocytic leukemia using ATRA (45 mg/m2), enocitabine (170 mg/m2, 5 days), and mitoxantrone (4 mg/m2, 3 days)." | 3.73 | [Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid]. ( Amaya, N; Arai, H; Lee, JD; Taga, M; Ueda, T; Yamauchi, T, 2005) |
| "We report the development of therapy-related early pre-B acute lymphoblastic leukemia in a patient administered a topoisomerase II inhibitor, etoposide, a consolidation therapy agent for acute promyelocytic leukemia." | 3.72 | MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia. ( Kondo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suemori, S; Suetsugu, Y; Sugihara, T; Tsujioka, T; Wada, H; Yamamori, S, 2003) |
| "To determine prognosis of acute promyelocytic leukemia (APL) failing to front-line therapy with all-trans retinoic acid (ATRA) and anthracyclines, outcome of 52 patients (32 M/20 F; age: 37, 3-72) included in PETHEMA trials LPA96 and LPA99 who presented with either molecular failure (MOLrel, n=16) or hematological relapse (HEMrel, n=36) was analyzed." | 2.73 | Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. ( Alvarez, C; Bolufer, P; Brunet, S; Colomer, D; Díaz-Mediavilla, J; Escoda, L; Esteve, J; González San Miguel, JD; González, M; Martín, G; Rivas, C; Rubio, V; Sánchez Godoy, P; Sanz, MA; Sayas, MJ; Tomás, JF; Tormo, M, 2007) |
| "Seventy adults with acute promyelocytic leukemia were studied to clarify the significance of the level and kinetics of minimal residual disease (MRD) over their entire treatment course by realtime quantitative polymerase chain reaction." | 2.72 | The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial. ( Cho, SG; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS, 2006) |
| "Molecular relapse was defined as reappearance of RT-PCR-positivity for the PML/RARalpha fusion (sensitivity 10(-4)) in 2 successive marrow samples collected during postconsolidation monitoring." | 2.69 | Therapy of molecular relapse in acute promyelocytic leukemia. ( Avvisati, G; Biondi, A; Carlo-Stella, C; Diverio, D; Lo Coco, F; Mandelli, F; Martino, B; Meloni, G; Petti, MC; Pogliani, EM; Rossi, G; Selleri, C; Specchia, G, 1999) |
| "Seventeen patients with APL were salvaged with ATRA at a dosage of 50 mg/m2/day for 3 months or until complete remission (CR) was achieved; idarubicin (12 mg/m2/day for 4 days) was added if blast plus promyelocyte count either was or reached > or = 10 x 10(3)/microliters." | 2.67 | All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. ( Cortes, JE; Estey, E; Hirsh-Ginsberg, C; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Robertson, LE; Stass, S, 1994) |
| "Of 40 patients with AML M3 or M3 v complete remission was attained in 62." | 2.67 | Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group. ( Becher, R; Fonatsch, C; Gassmann, W; Haase, D; Haferlach, T; Jürgensen, C; Löffler, H; Ludwig, WD; Noak, J; Thiel, E, 1993) |
| "Therapeutic advances in acute promyelocytic leukemia (APL) have transformed it into today's most curable form of leukemia." | 1.91 | Assessing the Efficacy of Mitoxantrone and Doxorubicin as Frontline Anthracyclines During Induction Therapy of Newly Diagnosed Acute Promyelocytic Leukemia. ( Gómez-Almaguer, D; González-Treviño, M; Jaime-Pérez, JC; Meléndez-Flores, JD; Ramos-Dávila, EM, 2023) |
| "This proadifen-MTX synergism was also mediated by the inhibition of various cellular proteins engaged in apoptosis, including Mc-1, Bcl-xL, survivin and activation of procaspase-3." | 1.42 | Downregulation of BCRP and anti-apoptotic proteins by proadifen (SKF-525A) is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells. ( Fedoročko, P; Hiľovská, L; Jendželovská, Z; Jendželovský, R; Kovaľ, J, 2015) |
| "All-trans retinoic acid (ATRA) has made acute promyelocytic leukemia (APL) a very curable disease also in patients aged >60 years; however, there are only few case reports in very elderly APL patients." | 1.42 | Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age. ( Avvisati, G; Breccia, M; Carmosino, I; Chisini, M; Cimino, G; Colafigli, G; Finsinger, P; Foà, R; Girmenia, C; Latagliata, R; Lo-Coco, F; Minotti, C; Montagna, C; Petti, MC; Romano, A; Volpicelli, P; Vozella, F, 2015) |
| "Treatment of acute promyelocytic leukemia (APL) with a combination of anthracycline-based chemotherapy and all-trans retinoic acid (ATRA) leads to very high rates of complete remission and survival." | 1.35 | Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia. ( Mellink, CH; Snijder, S; van der Lelie, H, 2008) |
| "We report the second case of acute promyelocytic leukemia (APL), which developed post-transplant and immunosuppressive treatment, in a 50-year-old male who had undergone a renal transplant." | 1.31 | Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case. ( Cuneo, A; Liso, V; Mestice, A; Pannunzio, A; Rocchi, M; Specchia, G; Storlazzi, CT; Surace, C, 2001) |
| "Mucormycosis is a rare fungal infection that has been described mainly in oncologic and diabetic patients." | 1.29 | [Pulmonary mucormycosis in leukemic patients. Apropos of 2 cases]. ( Cancelas, JA; Cerveró, C; García-Laraña, J; López, J; Navarro, JL; Odriozola, J; Pérez-Oteyza, J; Sánchez-Sousa, A; Sastre, JL, 1994) |
| "To evaluate our experience in the treatment of disseminated intravascular coagulation (DIC) associated to AML-M3 with substitution therapy with or without heparin." | 1.29 | [Therapy of disseminated intravascular coagulation in acute promyelocytic leukemias. Apropos of 19 cases]. ( Batlle, J; López Fernández, MF; Rodríguez Gómez, M, 1993) |
| "This paper describes two cases of acute promyelocytic leukemia diagnosed during the second trimester of pregnancy and the most suitable approach to the management of this situation is analyzed." | 1.29 | Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases. ( Gonzalez-Gonzalez, A; Pinilla, J; Requena, A; Velasco, JG, 1995) |
| "We report a case of an acute promyelocytic leukemia patient who showed remarkable thrombopoiesis prior to granulopoiesis by human macrophage colony-stimulating factor (hM-CSF) treatment after chemotherapy." | 1.28 | [A case report of an acute promyelocytic leukemia patient showing remarkable thrombopoiesis prior to granulopoiesis by hM-CSF treatment after chemotherapy]. ( Akiyoshi, T; Hisano, S; Ishibashi, M; Kimura, N; Morioka, E; Okumura, M; Suzumiya, J; Uchida, T, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 24 (33.33) | 18.2507 |
| 2000's | 28 (38.89) | 29.6817 |
| 2010's | 19 (26.39) | 24.3611 |
| 2020's | 1 (1.39) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, CC | 1 |
| Dong, Q | 1 |
| Liu, DF | 1 |
| Luo, YL | 1 |
| Liu, LF | 1 |
| Chen, AY | 1 |
| Yu, C | 1 |
| Savaraj, N | 1 |
| Chou, TC | 1 |
| Jaime-Pérez, JC | 2 |
| Ramos-Dávila, EM | 1 |
| Meléndez-Flores, JD | 1 |
| González-Treviño, M | 1 |
| Gómez-Almaguer, D | 2 |
| Zhu, HH | 1 |
| Guo, ZP | 1 |
| Jia, JS | 1 |
| Jiang, Q | 1 |
| Jiang, H | 1 |
| Huang, XJ | 1 |
| Zhou, JH | 1 |
| Lin, HQ | 1 |
| Shen, Q | 1 |
| Hu, LN | 1 |
| Li, GQ | 1 |
| Sun, XF | 1 |
| Zhang, XY | 1 |
| Franke, M | 1 |
| Theurich, S | 1 |
| Beyer, F | 1 |
| Persigehl, T | 1 |
| Ottone, T | 4 |
| Hasan, SK | 5 |
| Voso, MT | 3 |
| Ledda, A | 3 |
| Montefusco, E | 3 |
| Fenu, S | 1 |
| Pagoni, M | 1 |
| Hubmann, M | 1 |
| Lunghi, M | 2 |
| Platzbecker, U | 1 |
| Lo-Coco, F | 8 |
| Ruben, JM | 1 |
| van den Ancker, W | 1 |
| Bontkes, HJ | 1 |
| Westers, TM | 1 |
| Hooijberg, E | 1 |
| Ossenkoppele, GJ | 1 |
| de Gruijl, TD | 1 |
| van de Loosdrecht, AA | 1 |
| Sanz, MA | 7 |
| Iacoboni, G | 1 |
| Montesinos, P | 1 |
| Iland, HJ | 1 |
| Wei, A | 1 |
| Seymour, JF | 1 |
| Finsinger, P | 1 |
| Breccia, M | 2 |
| Minotti, C | 1 |
| Carmosino, I | 2 |
| Girmenia, C | 1 |
| Chisini, M | 1 |
| Volpicelli, P | 1 |
| Vozella, F | 1 |
| Romano, A | 1 |
| Montagna, C | 1 |
| Colafigli, G | 1 |
| Cimino, G | 3 |
| Avvisati, G | 6 |
| Petti, MC | 5 |
| Foà, R | 1 |
| Latagliata, R | 2 |
| Braun, T | 1 |
| Cereja, S | 1 |
| Chevret, S | 1 |
| Raffoux, E | 1 |
| Beaumont, M | 1 |
| Detourmignies, L | 1 |
| Pigneux, A | 2 |
| Thomas, X | 2 |
| Bordessoule, D | 1 |
| Guerci, A | 2 |
| Lamy, T | 1 |
| Recher, C | 1 |
| Poiré, X | 1 |
| Tournilhac, O | 1 |
| Spertini, O | 1 |
| Chomienne, C | 4 |
| Degos, L | 3 |
| Dombret, H | 2 |
| Adès, L | 2 |
| Fenaux, P | 4 |
| Hiľovská, L | 1 |
| Jendželovský, R | 1 |
| Jendželovská, Z | 1 |
| Kovaľ, J | 1 |
| Fedoročko, P | 1 |
| González-Leal, XJ | 1 |
| Pinzón-Uresti, MA | 1 |
| Gómez-De León, A | 1 |
| Cantú-Rodríguez, OG | 1 |
| Gutiérrez-Aguirre, H | 1 |
| Roengvoraphoj, M | 1 |
| Yan, S | 1 |
| Lansigan, F | 1 |
| Chapman, MS | 1 |
| Danilov, AV | 1 |
| Tang, YL | 1 |
| Chia, WK | 1 |
| Yap, EC | 1 |
| Julia, MI | 1 |
| Leong, CF | 1 |
| Salwati, S | 1 |
| Wong, CL | 1 |
| Mays, AN | 3 |
| La Nasa, G | 2 |
| Cattaneo, C | 2 |
| Borlenghi, E | 2 |
| Melillo, L | 1 |
| Cervera, J | 1 |
| Stephen, C | 1 |
| Satchi, G | 1 |
| Lennard, A | 1 |
| Libura, M | 1 |
| Byl, JA | 2 |
| Osheroff, N | 3 |
| Amadori, S | 3 |
| Felix, CA | 3 |
| Sperr, WR | 1 |
| Esteve, J | 3 |
| Grimwade, D | 4 |
| Bosca, I | 1 |
| Pascual, AM | 1 |
| Casanova, B | 1 |
| Coret, F | 1 |
| Ko, MW | 1 |
| Tamhankar, MA | 1 |
| Volpe, NJ | 1 |
| Porter, D | 1 |
| McGrath, C | 1 |
| Galetta, SL | 1 |
| Pielen, A | 1 |
| Goffette, S | 1 |
| Van Pesch, V | 1 |
| Gille, M | 1 |
| Sindic, CJ | 1 |
| Ellis, R | 1 |
| Boggild, M | 1 |
| Ammatuna, E | 1 |
| Pacilli, M | 1 |
| Divona, M | 1 |
| Ardiri, D | 1 |
| Centonze, D | 2 |
| Betancourt-García, RD | 1 |
| Castro, J | 1 |
| Fernández, AC | 1 |
| López-Enríquez, A | 1 |
| Fradera, J | 1 |
| Pacheco, E | 1 |
| Xiao, Y | 2 |
| Wiemels, JL | 3 |
| Saravanamuttu, K | 1 |
| Peniket, A | 1 |
| Corser, R | 1 |
| Chang, C | 1 |
| Hoyle, C | 1 |
| Parker, AN | 1 |
| Solomon, E | 2 |
| Schlenk, RF | 2 |
| Mitra, ME | 1 |
| Bernasconi, P | 1 |
| Di Raimondo, F | 1 |
| Stanghellini, MT | 1 |
| Marco, P | 1 |
| Döhner, H | 2 |
| Buttari, F | 1 |
| Hohaus, S | 1 |
| Marasco, E | 1 |
| Mantovani, V | 1 |
| Garagnani, P | 1 |
| Cicconi, L | 1 |
| Bernardi, G | 1 |
| Taube, F | 1 |
| Stölzel, F | 1 |
| Thiede, C | 1 |
| Ehninger, G | 1 |
| Laniado, M | 1 |
| Schaich, M | 1 |
| Mikusová, V | 1 |
| Tichý, A | 1 |
| Rezáčová, M | 1 |
| Vávrová, J | 1 |
| Lengfelder, E | 2 |
| Hanfstein, B | 1 |
| Haferlach, C | 1 |
| Braess, J | 1 |
| Krug, U | 1 |
| Spiekermann, K | 1 |
| Haferlach, T | 2 |
| Kreuzer, KA | 1 |
| Serve, H | 1 |
| Horst, HA | 1 |
| Schnittger, S | 1 |
| Aul, C | 1 |
| Schultheis, B | 1 |
| Erben, P | 1 |
| Schneider, S | 1 |
| Müller-Tidow, C | 1 |
| Wörmann, B | 1 |
| Berdel, WE | 1 |
| Sauerland, C | 1 |
| Heinecke, A | 1 |
| Hehlmann, R | 2 |
| Hofmann, WK | 1 |
| Hiddemann, W | 2 |
| Büchner, T | 1 |
| Almici, C | 1 |
| Motta, M | 1 |
| Rossi, G | 2 |
| Kröger, N | 1 |
| Damon, L | 1 |
| Zander, AR | 1 |
| Wandt, H | 1 |
| Derigs, G | 1 |
| Ferrante, P | 1 |
| Demirer, T | 1 |
| Rosti, G | 1 |
| Tsujioka, T | 1 |
| Wada, H | 1 |
| Yamamori, S | 1 |
| Otsuki, T | 1 |
| Suemori, S | 1 |
| Kondo, T | 1 |
| Nakanishi, H | 1 |
| Suetsugu, Y | 1 |
| Mikami, M | 1 |
| Sugihara, T | 1 |
| Novoselac, AV | 1 |
| Reddy, S | 1 |
| Sanmugarajah, J | 1 |
| Bozdağ, S | 1 |
| Capan, Y | 1 |
| Vural, I | 1 |
| Dalkara, T | 1 |
| Dogan, AL | 1 |
| Guc, D | 1 |
| Hincal, AA | 1 |
| Deluca, PP | 1 |
| Mistry, AR | 1 |
| Whitmarsh, RJ | 1 |
| Mason, A | 1 |
| Reiter, A | 1 |
| Cassinat, B | 1 |
| Parry, A | 1 |
| Walz, C | 1 |
| Segal, MR | 1 |
| Blair, IA | 1 |
| Peniket, AJ | 1 |
| Lafage-Pochitaloff, M | 1 |
| Cross, NC | 1 |
| Germing, U | 1 |
| Hartmann, F | 1 |
| Glasmacher, A | 1 |
| Fischer, JT | 1 |
| del Valle y Fuentes, F | 1 |
| Götze, K | 1 |
| Pralle, H | 1 |
| Nerl, C | 1 |
| Salwender, H | 1 |
| Grimminger, W | 1 |
| Petzer, A | 1 |
| Hensel, M | 1 |
| Benner, A | 1 |
| Zick, L | 1 |
| Döhner, K | 1 |
| Fröhling, S | 1 |
| Arruda, WO | 1 |
| Montú, MB | 1 |
| de Oliveira, Mde S | 1 |
| Ramina, R | 1 |
| Yamauchi, T | 1 |
| Arai, H | 1 |
| Taga, M | 1 |
| Amaya, N | 1 |
| Lee, JD | 1 |
| Ueda, T | 1 |
| Lee, S | 1 |
| Kim, YJ | 1 |
| Eom, KS | 1 |
| Min, CK | 1 |
| Kim, HJ | 1 |
| Cho, SG | 1 |
| Lee, JW | 1 |
| Min, WS | 1 |
| Kim, CC | 1 |
| Caocci, G | 1 |
| Spinicci, G | 1 |
| Cocco, E | 1 |
| Mamusa, E | 1 |
| Minni, A | 1 |
| Testi, A | 1 |
| Iorio, N | 1 |
| Mandelli, F | 5 |
| Escoda, L | 1 |
| Martín, G | 2 |
| Rubio, V | 1 |
| Díaz-Mediavilla, J | 2 |
| González, M | 3 |
| Rivas, C | 1 |
| Alvarez, C | 1 |
| González San Miguel, JD | 1 |
| Brunet, S | 1 |
| Tomás, JF | 1 |
| Tormo, M | 1 |
| Sayas, MJ | 1 |
| Sánchez Godoy, P | 1 |
| Colomer, D | 2 |
| Bolufer, P | 2 |
| Klein, SK | 1 |
| Biemond, BJ | 1 |
| van Oers, MH | 1 |
| Snijder, S | 1 |
| Mellink, CH | 1 |
| van der Lelie, H | 1 |
| Ramkumar, B | 1 |
| Chadha, MK | 1 |
| Barcos, M | 1 |
| Sait, SN | 1 |
| Heyman, MR | 1 |
| Baer, MR | 1 |
| Sastre, JL | 1 |
| Pérez-Oteyza, J | 1 |
| López, J | 1 |
| Cerveró, C | 1 |
| Sánchez-Sousa, A | 1 |
| García-Laraña, J | 1 |
| Cancelas, JA | 1 |
| Odriozola, J | 1 |
| Navarro, JL | 1 |
| Todisco, E | 1 |
| Testi, AM | 1 |
| Moleti, ML | 1 |
| Cedrone, M | 1 |
| Mancini, F | 1 |
| Harker, WG | 1 |
| Slade, DL | 1 |
| Parr, RL | 1 |
| Feldhoff, PW | 1 |
| Sullivan, DM | 1 |
| Holguin, MH | 1 |
| Chastang, C | 1 |
| Castaigne, S | 1 |
| Sanz, M | 1 |
| Link, H | 2 |
| Löwenberg, B | 1 |
| Fey, M | 1 |
| Archim-Baud, E | 1 |
| Azuno, Y | 1 |
| Kaku, K | 1 |
| Fujita, N | 1 |
| Okubo, M | 1 |
| Kaneko, T | 1 |
| Matsumoto, N | 1 |
| Cai, S | 1 |
| Chen, J | 1 |
| Ye, S | 1 |
| Yu, F | 1 |
| Dreosti, LM | 1 |
| Bezwoda, W | 1 |
| Gunter, K | 1 |
| Simon, M | 1 |
| Haase, D | 2 |
| Hild, F | 1 |
| Rodríguez Gómez, M | 1 |
| López Fernández, MF | 1 |
| Batlle, J | 1 |
| Cortes, JE | 1 |
| Kantarjian, H | 1 |
| O'Brien, S | 1 |
| Robertson, LE | 1 |
| Koller, C | 1 |
| Hirsh-Ginsberg, C | 1 |
| Stass, S | 1 |
| Keating, M | 1 |
| Estey, E | 1 |
| Gassmann, W | 1 |
| Löffler, H | 1 |
| Jürgensen, C | 1 |
| Noak, J | 1 |
| Ludwig, WD | 1 |
| Thiel, E | 1 |
| Fonatsch, C | 1 |
| Becher, R | 1 |
| Requena, A | 1 |
| Velasco, JG | 1 |
| Pinilla, J | 1 |
| Gonzalez-Gonzalez, A | 1 |
| Tobita, T | 1 |
| Shinjyo, K | 1 |
| Yanagi, M | 1 |
| Takeshita, A | 1 |
| Ohnishi, K | 1 |
| Ohno, R | 2 |
| Meloni, G | 2 |
| Diverio, D | 2 |
| Vignetti, M | 1 |
| Capria, S | 1 |
| Lo Coco, F | 3 |
| Vicari, AM | 1 |
| Ciceri, F | 1 |
| Folli, F | 1 |
| Lanzi, R | 1 |
| Colombo, B | 1 |
| Comi, G | 1 |
| Camba, L | 1 |
| Castagnola, C | 1 |
| Corso, A | 1 |
| Tajana, M | 1 |
| Zappasodi, P | 1 |
| Dabusti, M | 1 |
| Lazzarino, M | 1 |
| Bernasconi, C | 2 |
| Batlle, M | 1 |
| Fernández-Avilés, F | 1 |
| Ribera, JM | 2 |
| Millá, F | 1 |
| Granada, I | 1 |
| Gómez Espuch, J | 1 |
| Navarro, JT | 1 |
| Feliu, E | 1 |
| Gutiérrez, NC | 1 |
| García, JL | 1 |
| Chillón, C | 1 |
| Muntión, S | 1 |
| Hernández, JM | 1 |
| Sousa, AB | 1 |
| Fernandes, JP | 1 |
| Ferreira, G | 1 |
| Bernardo, M | 1 |
| Conduto, A | 1 |
| Costa, I | 1 |
| Cruz, E | 1 |
| Gonçalves, AJ | 1 |
| Monteiro, A | 1 |
| Nunes, O | 1 |
| Ribeiro, P | 1 |
| Rodrigues, AS | 1 |
| Sousa, M | 1 |
| Veiga, J | 1 |
| Gouveia, J | 1 |
| Pogliani, EM | 1 |
| Biondi, A | 1 |
| Carlo-Stella, C | 1 |
| Selleri, C | 1 |
| Martino, B | 1 |
| Specchia, G | 2 |
| Cordonnier, C | 1 |
| Gardin, C | 1 |
| Vekhoff, A | 1 |
| Sadoun, A | 1 |
| Stamatoullas, A | 1 |
| Fegueux, N | 1 |
| Maloisel, F | 1 |
| Cahn, JY | 1 |
| Reman, O | 1 |
| Gratecos, N | 1 |
| Berthou, C | 1 |
| Huguet, F | 1 |
| Kotoucek, P | 1 |
| Travade, P | 1 |
| Buzyn, A | 1 |
| de Revel, T | 1 |
| Vilque, JP | 1 |
| Naccache, P | 1 |
| Rayón, C | 1 |
| Barbui, T | 1 |
| Fioritoni, G | 1 |
| González, JD | 1 |
| Liso, V | 2 |
| Ferrara, F | 1 |
| Rodeghiero, F | 1 |
| Asou, N | 1 |
| Adachi, K | 1 |
| Tamura, J | 1 |
| Kanamaru, A | 1 |
| Kageyama, S | 1 |
| Hiraoka, A | 1 |
| Omoto, E | 1 |
| Akiyama, H | 1 |
| Puga, BL | 1 |
| Cabrera, ME | 1 |
| Undurraga, MS | 1 |
| Etcheverry, R | 1 |
| Vacarezza, R | 1 |
| Ducach, G | 1 |
| Toledo, H | 1 |
| Storlazzi, CT | 1 |
| Cuneo, A | 1 |
| Surace, C | 1 |
| Mestice, A | 1 |
| Pannunzio, A | 1 |
| Rocchi, M | 1 |
| Takeuchi, N | 1 |
| Nakamura, T | 1 |
| Takeuchi, F | 1 |
| Hashimoto, E | 1 |
| Yamamura, H | 1 |
| Suzumiya, J | 1 |
| Morioka, E | 1 |
| Kimura, N | 1 |
| Ishibashi, M | 1 |
| Uchida, T | 1 |
| Akiyoshi, T | 1 |
| Hisano, S | 1 |
| Okumura, M | 1 |
| Freund, M | 1 |
| Wunsch-Zeddies, S | 1 |
| Schäfers, M | 1 |
| Wysk, J | 1 |
| Seidel, I | 1 |
| Hanauske, AR | 1 |
| Schmoll, HJ | 1 |
| Poliwoda, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness and Safety of Therapy Based on Attenuated Arsenic Trioxide Plus Low Doses of All-trans Retinoic Acid as Remission Induction Therapy in Patients With Acute Promyelocytic Leukemia Phase 1/2 Clinical Trial[NCT05497310] | Phase 1/Phase 2 | 15 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| Chemical Exposures and Leukemia Risks and Childhood Leukemia and Environmental Exposure[NCT00015587] | 3,523 participants (Actual) | Observational | 1995-04-30 | Completed | |||
| Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted Consolidation With ATRA and Anthracycline-based Chemotherapy (Idarubicin/Mitoxantrone) With Addition of Ar[NCT00408278] | Phase 4 | 300 participants (Anticipated) | Interventional | 2005-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for mitoxantrone and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
Conventional induction and post-remission therapy in APL: have we arrived?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinic | 2014 |
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2014 |
Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chromosome | 2009 |
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantat | 2003 |
Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Idarubicin; Leukemia, Promyel | 2007 |
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Diffe | 1995 |
11 trials available for mitoxantrone and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Tri | 2018 |
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyro | 2005 |
The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; | 2006 |
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; C | 2007 |
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Diffe | 1995 |
All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Drug | 1994 |
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Daunorubicin; Humans; Le | 1993 |
Short-term intensive consolidation therapy after all-trans retinoic acid in acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, P | 1999 |
Therapy of molecular relapse in acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Humans; | 1999 |
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; | 2000 |
[Treatment of acute promyelocytic leukemia with all-trans retinoic acid and chemotherapy--multicenter trial of the Japan Adult Leukemia Study Group (JALSG)].
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2000 |
56 other studies available for mitoxantrone and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; DNA Topoisomerases, Type II; Furans; Humans | 1993 |
Assessing the Efficacy of Mitoxantrone and Doxorubicin as Frontline Anthracyclines During Induction Therapy of Newly Diagnosed Acute Promyelocytic Leukemia.
Topics: Anthracyclines; Doxorubicin; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Mitoxan | 2023 |
Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2018 |
[Pulmonary differentiation -/ATRA syndrome within the scope of therapy of acute promyelocytic leukemia (APL)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, Differential; D | 2014 |
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Breakpoints; Chromosomes, Human, Pair 15; Chromosomes | 2014 |
Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines.
Topics: Antigen Presentation; Antigens, Neoplasm; Apoptosis; Cancer Vaccines; Cell Movement; Cell-Derived Mi | 2014 |
Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Fema | 2015 |
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Belgium; Chemoradiother | 2015 |
Downregulation of BCRP and anti-apoptotic proteins by proadifen (SKF-525A) is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, | 2015 |
Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Tr | 2015 |
Acute inflammatory skin reaction during neutrophil recovery after antileukemic therapy.
Topics: Adult; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Humans; Leukemia, Promyelocy | 2016 |
Dismal outcome of therapy-related myeloid neoplasm associated with complex aberrant karyotypes and monosomal karyotype: a case report.
Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Humans; Idarubicin; In Situ Hybr | 2016 |
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.
Topics: Adult; Antigens, Neoplasm; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; DNA; DNA Topois | 2008 |
Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone.
Topics: Adolescent; Adult; Child; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Ag | 2008 |
Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.
Topics: Analgesics; Female; Humans; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Middle Aged; | 2008 |
Mitoxantrone-related acute leukemia in two MS patients.
Topics: Adult; Analgesics; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; M | 2008 |
Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
Topics: Acute Disease; Adult; Antineoplastic Agents; Databases, Factual; Female; Humans; Leukemia, Myeloid, | 2009 |
Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Enzyme Inhibitors; Humans; Leukemia, Pro | 2009 |
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Huma | 2010 |
Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Breakpoints; Chromosomes, Human, Pair 15; Chromosomes | 2010 |
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.
Topics: Adult; Antineoplastic Agents; DNA Repair Enzymes; Genetic Predisposition to Disease; Humans; Leukemi | 2011 |
Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
Topics: Antineoplastic Agents; Female; Humans; Intracranial Hemorrhages; Leukemia, Promyelocytic, Acute; Mid | 2011 |
Mitoxantrone in combination with a DNA-PK inhibitor: possible therapy of promyelocytic leukaemia resistant forms.
Topics: Acid Anhydride Hydrolases; Antineoplastic Agents; Cell Cycle Proteins; DNA Breaks, Double-Stranded; | 2011 |
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxi | 2013 |
A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.
Topics: Antineoplastic Agents; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Mult | 2003 |
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Huma | 2003 |
Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone.
Topics: Adult; Antineoplastic Agents; Female; Humans; Leukemia, Promyelocytic, Acute; Mitoxantrone; Multiple | 2004 |
In vitro cytotoxicity of mitoxantrone-incorporated albumin microspheres on acute promyelocytic leukaemia cells.
Topics: Animals; Antibiotics, Antineoplastic; Drug Carriers; Drug Compounding; HL-60 Cells; Humans; Leukemia | 2004 |
DNA topoisomerase II in therapy-related acute promyelocytic leukemia.
Topics: Antineoplastic Agents; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubic | 2005 |
Acute myeloid leukaemia induced by mitoxantrone: case report.
Topics: Fatal Outcome; Female; Humans; Immunosuppressive Agents; Leukemia, Promyelocytic, Acute; Middle Aged | 2005 |
[Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Heart Bloc | 2005 |
Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis.
Topics: Adult; Female; Humans; Immunosuppressive Agents; Leukemia, Promyelocytic, Acute; Mitoxantrone; Multi | 2006 |
Late relapses in acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytara | 2007 |
Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Chromosomes, Human, Pair 11; Chromo | 2008 |
Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 11; Female; Humans; In Situ Hybridization, Fluoresce | 2008 |
[Pulmonary mucormycosis in leukemic patients. Apropos of 2 cases].
Topics: Adult; Aged; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fatal Outco | 1994 |
Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 10; Chromosomes | 1995 |
Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Topics: Base Sequence; Cell Line; DNA Primers; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; | 1995 |
Mitoxantrone and etoposide in breast milk.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Leukemia, Promyelo | 1995 |
[Effect of prednisolon, vincristine and mitoxantrone on glucocorticoid receptor in HL-60 cell line].
Topics: Dose-Response Relationship, Drug; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mitoxantro | 1994 |
Bone marrow necrosis following ALL-trans retinoic acid therapy for acute promyelocytic leukaemia.
Topics: Bone Marrow; Female; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Leukocyte Count; L | 1994 |
[Complete remission in acute promyelocytic leukemia. The advantages of all-trans-retinoic acid compared to conventional chemotherapy].
Topics: Adult; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; D | 1994 |
[Therapy of disseminated intravascular coagulation in acute promyelocytic leukemias. Apropos of 19 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Blood Coa | 1993 |
Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases.
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tran | 1995 |
Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modalit | 1997 |
Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biom | 1997 |
Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis.
Topics: Adult; Humans; Leukemia, Promyelocytic, Acute; Male; Mitoxantrone; Multiple Sclerosis; Topoisomerase | 1998 |
Management of acute promyelocytic leukemia relapse in the ATRA era.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1998 |
Acute promyelocytic leukemia in a patient with idiopathic myelofibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydroxyurea; Idarubicin; Leuke | 1999 |
Cryptic insertion (15;17) in a case of acute promyelocytic leukemia detected by fluorescence in situ hybridization.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chr | 1999 |
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; | 2000 |
[Acute myeloid leukemia in the adult. Results of the National Antineoplastic Drug Protocol at the Hospital del Salvador, 1990-1998].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyt | 2000 |
Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 1; | 2001 |
Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells.
Topics: Animals; Brain; Casein Kinases; Cell Division; Chromatography, Ion Exchange; Dose-Response Relations | 1992 |
[A case report of an acute promyelocytic leukemia patient showing remarkable thrombopoiesis prior to granulopoiesis by hM-CSF treatment after chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Granulocytes; Hematopoiesi | 1992 |
Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, | 1992 |